Methodist University Hospital completes first Barostim implant with CVRx collaboration

Methodist University Hospital completes first Barostim implant with CVRx collaboration
CVRx, hospital in heart device deal

CVRx and Methodist University Hospital have announced the successful completion of the hospital's first Barostim implant, a novel device therapy aimed at improving symptoms for patients with heart failure.

This partnership, involving Dr. Jonathan Nitz, Dr. Yehoshua Levine, and the medical team, underscores a significant step forward in making advanced treatment options available to more patients. The Barostim system is designed to provide new hope for those who have not responded to conventional heart failure therapies.

CVRx recently projected first-quarter 2026 revenue growth of 20 percent, expecting $14.7 million to $14.8 million in sales compared with a year earlier, according to preliminary results. The company also featured its Barostim device in an expert session at ISHLT2026, focusing on innovations in heart failure care, as detailed in a separate announcement. These developments come as CVRx expands Barostim’s clinical presence.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.